Apparatus for the non-invasive in-vivo determination of changes in tissue, e.g. the myelination, of the optic nerve (ON) in a biological subject, said apparatus comprising: a laser source for generating an excitation laser beam; an optical system including a fundus camera operatively associated with the laser source for use in obtaining a fundus image for illuminating the optic nerve (ON) of a subject with the excitation laser beam; a detector (13) operatively associated with the optical system and configured to detect a Raman spectrum from the optic nerve (ON) and/or surrounding cerebral spinal fluid; and a processor provided with a computer program for comparing the detected Raman spectrum to at least one reference spectrum. The reference spectrum may correspond to the myelination of the optic nerve in a normal, healthy subject, for determining the changes in the myelination of the optic nerve of the subject based on the detecting and comparing steps from the Raman spectrum.

A method for creating calibration data for processing accelerated measurement data of an object to be examined using a magnetic resonance system. The method includes recording measurement data sets using an acquisition acceleration method, recording calibration data sets, and determining processed measurement data sets from the accelerated measurement data sets using the calibration data sets so that effects of the acquisition acceleration method used are eliminated in the processed measurement data sets. The recording of the calibration data sets includes an application of at least one attenuation method for attenuating signals causing phase errors.

Methods for treating bestrophinopathies are provided herein. The method includes, administering to an eye of the subject a dose of a recombinant adeno-associated virus (rAAV) vector comprising a nucleic acid sequence encoding a human BEST1 protein, wherein the subject has two mutant BEST1 alleles. Also provided are methods for evaluating treatments for retinal degeneration.

Computational approaches to assess CNS functionality using a digital tablet and stylus are provided.

A balance prosthesis device for an individual including a sensor module configured to obtain a sensor signal indicative of a balance or equilibrium state of the individual, a processing module configured to determine at least one neurostimulation signal based at least in part on the obtained sensor signal, and a transmitter module configured to transmit the determined neurostimulation signal to a neurostimulation device of the individual. The neurostimulation signal is configured to elicit an artificial sensation in a specific sensory cortex area of the individual via directly stimulating afferent sensory axons of the central or peripheral nervous system of the individual targeting sensory neurons of the sensory cortex area not directly associated with vestibulocortical pathways of the individual. The elicited artificial sensation provides a balance indication to the individual in order to support, mimic, substitute or enhance the natural sense of balance of the individual.

Systems and methods for closed-loop control of electrostimulation while avoiding, or maintaining a substantially low level of, evoked neural activity are disclosed. A system comprises an electrostimulator to deliver a stimulation pulse train, a sensing circuit to sense evoked responses to respective pulses in the pulse train, and a controller to detect an evoked neural activity from an averaged evoked response by averaging evoked responses to respective pulses. The averaging operation can be controlled by a noise level of the averaged evoked response, or by a count of epochs (pulses) being used for averaging. Responsive to the evoked neural activity satisfying a detection criterion, the controller recursively adjusts stimulation parameters until the detection criterion is no longer satisfied. The electrostimulator delivers electrostimulation according to the recursively adjusted stimulation parameters.

Methods for treating bestrophinopathies are provided herein. The method includes, administering to an eye of the subject a dose of a recombinant adeno-associated virus (rAAV) vector comprising a nucleic acid sequence encoding a human BEST1 protein, wherein the subject has at least one mutant BEST1 allele. Also provided are methods for evaluating treatments for retinal degeneration.

The invention provides methods for diagnosing, assessing or quantitating drug use, drug abuse or narcosis or for differentiating drug use, drug abuse or narcosis from brain injury in a subject by tracking eye movement of at least one eye of the subject, analyzing eye movement of at least one eye of the subject, comparing eye movement of at least one eye of the subject the normal or mean eye movement; and, optionally calculating a standard deviation or p value for eye movement of at least one eye of the subject as compared to the normal or mean eye movement.

A neural control system comprises an input controller arranged to receive neural data regarding neural signals relating to a bodily state of a subject from at least one neural sensor, at least one machine learning means using at least one machine learning model to process the received neural data to determine at least one output signal required to achieve a desired value of the bodily state, and means arranged to send the determined output signal to at least one output device, whereby the neural control system forms a first control loop providing closed loop control of the bodily state.

A system and method for in-vivo monitoring for changes in body proteins over time includes an intelligent, implantable image capture system. An embedded processor controls activation of lighting for imaging proteins in surrounding tissue. A base image is captured and resulting data used in comparison with image data from one or more subsequent image captures to indicate progression of tissue changes, such as may occur with diseased tissue.